J&J quietly punts a pair of early-stage bispecifics for solid tumors

Johnson & Johnson has put two early-stage bispecific antibodies on the backburner, the pharma giant revealed as part of its quarterly update.

Listed in the pipeline as recently as October, JNJ-6358 — a bispecific antibody binding to CD3 on T cells and human leukocyte antigen G (HLA-G) on cancer cells — and JNJ-8902 — a CD3 x TMEFF2 bispecific — were nowhere to be found in the latest pipeline presentation.